Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Full article: The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming

Pharmaceuticals, Free Full-Text

Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression

Frontiers Immune Checkpoint Inhibitors in Triple Negative Breast

Frontiers Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells

Triple negative breast cancer: special histological types and

Frontiers Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer

PDF] Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

IJMS, Free Full-Text

PDF] Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

IJMS, Free Full-Text